自然杀伤 (NK) 细胞在免疫系统对抗癌症的反应中发挥着至关重要的作用。然而，获得有效治疗反应所需数量的 NK 细胞的挑战需要制定其离体扩增策略。本研究旨在开发一种新型饲养细胞系 K562.Clone1，能够促进 NK 细胞的离体扩增NK 细胞，同时保留其细胞毒性潜力。用 mbIL-21 和 4-1BBL 蛋白转导 K562 白血病细胞系，生成 K562.Clone1 细胞。然后将 NK 细胞与这些饲养细胞共培养，并在 14 天内监测它们的扩增率。评估了扩增的 NK 细胞针对急性髓系白血病母细胞以及白血病和神经胶质来源的肿瘤细胞系的细胞毒性潜力。进行统计分析以确定结果的显着性。与外周NK共培养的K562.Clone1显示细胞计数显着增加，在14天内扩增了约94倍。扩增的 NK 细胞表现出针对测试的肿瘤细胞系的细胞毒性，表明其细胞毒性特征得以保留。此外，CD56、CD16、抑制性 KIR 和激活受体均得到保守并以良好平衡的方式存在。该研究成功开发了饲养细胞系 K562.Clone1，可有效促进 NK 细胞离体扩增，同时保持其活性。细胞毒性潜力。这一发展可以极大地促进 NK 细胞疗法的进步，特别是在巴西。版权所有 © 2024。由 Elsevier Inc. 出版。

Natural Killer (NK) cells play a crucial role in the immune system's response against cancer. However, the challenge of obtaining the required quantity of NK cells for effective therapeutic response necessitates the development of strategies for their ex vivo expansion.This study aimed to develop a novel feeder cell line, K562.Clone1, capable of promoting the ex vivo expansion of NK cells while preserving their cytotoxic potential.The K562 leukemic cell line was transduced with mbIL-21 and 4-1BBL proteins to generate K562.Clone1 cells. NK cells were then co-cultured with these feeder cells, and their expansion rate was monitored over 14 days. The cytotoxic potential of the expanded NK cells was evaluated against acute myeloid leukemia blasts and tumor cell lines of leukemia and glial origin. Statistical analysis was performed to determine the significance of the results.The K562.Clone1 co-cultured with peripheral NK showed a significant increase in cell count, with an approximately 94-fold expansion over 14 days. Expanded NK cells demonstrated cytotoxicity against the tested tumor cell lines, indicating the preservation of their cytotoxic characteristics. Additionally, the CD56, CD16, inhibitory KIRs, and activation receptors were conserved and present in a well-balanced manner.The study successfully developed a feeder cell line, K562.Clone1, that effectively promotes the expansion of NK cells ex vivo while maintaining their cytotoxic potential. This development could significantly contribute to the advancement of NK cell therapy, especially in Brazil.Copyright © 2024. Published by Elsevier Inc.